Personalized Medicine For You

Cancer

Cancer is a disease of abnormal gene function. Some gene changes that lead to cancer may be inherited. Breast, ovarian, prostate, and colon are some of these cancers that are linked to a family history. The genetic mutations that cause many of the known hereditary cancer syndromes have been identified, and genetic testing can confirm whether a condition is the result of an inherited syndrome. Genetic profiling may help you or other family members in planning health care for the future.

Hereditary Cancer Syndrome

myRisk™ – Myriad’s myRisk™ is a test developed by Myriad Genetic Laboratories that measures an individual’s risk of developing hereditary cancer syndromes.

Breast Cancer

Hereditary Breast and Ovarian Cancer
BRACAnalysis® – Myriad’s BRACAnalysis® test assesses a person’s risk of developing hereditary breast or ovarian cancer based on the detection of mutations in the BRCA1 and BRCA2 genes.

Necessity of Chemotherapy
EndoPredict® – Myriad’s EndoPredict® is a prognostic 2nd generation IVD gene expression test to determine the risk of distant metastases in patients with estrogen receptor positive, HER2-negative primary breast cancer.

Colorectal Cancer

Lynch Syndrome
COLARIS® – Myriad’s COLARIS® testing assesses a person’s risk of developing hereditary colorectal cancer and a woman’s risk of developing hereditary uterine/endometrial cancer by detecting disease-causing mutations in the MLH1, MSH2, MSH6 and PMS2 genes.

Polyposis Syndrome
COLARIS AP® – Myriad’s COLARIS AP® testing assesses a person’s risk of developing hereditary colorectal polyps and cancer by detecting mutations in the APC and MYH genes.

Prostate Cancer

Prolaris® – Myriad’s Prolaris® is a test that measures how fast the cells in your tumor are dividing. Since you have had a biopsy, that tissue sample can be used to determine your Prolaris Score.

Skin Cancer

Melaris® – Myriad’s Melaris® is a test developed by Myriad Genetic Laboratories that measures a person’s risk of developing hereditary melanoma.

Pancreatic Cancer

PANEXIA™ – Myriad’s PANEXIA™ is a genetic test specifically created to detect mutations in genes that result in an increased risk of pancreatic cancer, offering insight about the risk of future hereditary cancers for patients and their families.

Cardiovascular Diseases

The majority of cardiovascular disease (CVD) is caused by risk factors that can be controlled, treated or modified. However, there are some major CVD risk factors that cannot be controlled. Current risk functions evaluate characteristics which can only be identified once they appear, without considering other potential factors such as the patient’s genetic constitution. Genetic profiling may provide personalized information, enabling cardiovascular risk to be identified in a more precise manner.

Cardiac Sudden Death

SudD inCode® – Ferrer inCode’s SudD inCode® is a personalized medicine service that analyzes a patient’s genetic and clinical data to establish the presence of mutations (new or known) associated with the development of structural and arrhythmogenic heart diseases that can induce cardiac sudden death.

Coronary Artery Diseases (CAD)

Cardio inCode® – Ferrer inCode’s Cardio inCode® is a genetic test which evaluates an individual’s biomarkers related to the cardiovascular risk and helps to better establish the real cardiovascular risk of the patient.

Pediatric Disorders

Getting your child’s illness diagnosed might feel like a never-ending quest—especially if he or she is suffering from a complicated neurological or metabolic disorder such as mitochondrial disorder, epilepsy and seizure, or neuro- developmental disorder. Multiple lines of evidence support that genetic factors play a pivotal role in the etiology of these disorders. Your child’s unique genetic profile may help shed light on new information that could lead to a more accurate diagnosis and potential treatment options.

Epilepsy and Seizure Disorders

epiSEEK® (71 Genes) – Courtagen’s epiSEEK® Infancy and Childhood Epilepsy test is a next generation sequencing genetic assay. Courtagen extracts DNA from the patients’ saliva sample and analyzes it by searching for mutations in 71 genes highly associated with infancy and childhood onset of epilepsy and seizure disorders.

epiSEEK® (489 Genes) – Courtagen’s epiSEEK® Comprehensive Sequence Analysis for Epilepsy and Seizure Disorders is a next generation sequencing genetic test. Courtagen extracts DNA from the patients’ saliva sample and analyzes it by searching for mutations in 489 genes associated with epilepsy and seizure disorders.

Mitochondrial Diseases

mtSEEK® – Courtagen’s mtSEEK® test is a genetic test that identifies abnormalities in a person’s mitochondrial DNA (mtDNA). The analysis is performed from a saliva sample and sequences all 37 genes contained in the maternally inherited mtDNA.

nucSEEK® – Courtagen’s nucSEEK® is a genetic test that identifies changes in nuclear DNA that impact mitochondrial function. The nucSEEK® analysis is performed from a saliva sample and tests over a 1,100 genes in the nuclear mitochondrial exome.

Neurodevelopmental Disorders

devSEEK® – Courtagen’s devSEEK® is a genetic test that identifies changes in a person’s DNA. The devSEEK® analysis is performed from a saliva sample and tests for just over a hundred genes known to be associated with developmental delay, intellectual disability, and autism spectrum disorders.

devACT® – Courtagen’s devACT® is a genetic test that identifies changes in a person’s DNA. The devACT® analysis is performed from a saliva sample and tests for just over 200 genes, many of which indicate treatable disorders. If a rare genetic disorder is identified, targeted treatment options can result in significant improvement for your child.

Unknown Genetic Disorders

Rare genetic disorders can go undiagnosed for years. The lack of a diagnosis can have considerable adverse effects for patients and their families, including failure to identify potential treatments, failure to recognize risk of recurrence in subsequent pregnancies, and failure to provide anticipatory guidance and prognosis. Genetic testing has proven to be effective in detecting rare variants in an individual’s genome, offering hope to individuals with previously undiagnosed or untreated rare disorders.

ACE Clinical Exome™ – Personalis ACE Clinical Exome™ test differs from many other types of genetic tests because instead of looking at only one or a few genes, the test looks at approximately 20,000 genes in the human genome to arrive at a potential genetic cause and diagnosis